CYP2D6 Poor Metabolizer Status Can Be Ruled Out by a Single Genotyping Assay for the −1584G Promoter Polymorphism [PDF]
Andrea Gaedigk +3 more
openalex +1 more source
Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine-Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions. [PDF]
de la Cruz CG +5 more
europepmc +1 more source
Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer [PDF]
M. A. Province, Teri E. Klein
openalex +1 more source
StarTRAC-<i>CYP2D6</i>: a method for <i>CYP2D6</i> allele-specific copy number determination using digital PCR. [PDF]
Wang WY +4 more
europepmc +1 more source
Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen [PDF]
Masatsugu Okishiro +5 more
openalex +1 more source
Development and Validation of a Multigene Panel for Pharmacogenomics Testing Using Next-Generation Sequencing for Routine Clinical Practice. [PDF]
Hongkaew Y +7 more
europepmc +1 more source

